Contextual Genomics and Lab Genomics have signed an agreement enabling Lab Genomics to offer Contextual Genomics' quality assured Next Generation Sequencing (NGS) based ctDNA cancer genomic testing to patients in Southern California and other parts of the United States. Under the terms of their agreement, Lab Genomics will offer the FOLLOW IT panel, a test detecting cell-free circulating tumour DNA in plasma to patients diagnosed with cancer. The FOLLOW IT panel is a multiplex, NGS genomic assay designed for rapid deployment into labs around the world. The FOLLOW IT assay evaluates the mutation status of cell-free circulating tumour, identifying the somatic mutations that have the greatest potential to impact treatment decisions.